Radiotherapy with the anti-programmed cell death ligand-1 immune checkpoint blocker avelumab: acute toxicities in triple-negative breast cancer

Eliana La Rocca, Michela Dispinzieri, Laura Lozza, Gabriella Mariani, Serena Di Cosimo, Massimiliano Gennaro, Riccardo Valdagni, Maria Carmen De Santis

Research output: Contribution to journalArticle

Abstract

Triple-negative breast cancer (TNBC) is clinically the most aggressive breast cancer (BC) subtype. There is an urgent need for effective therapies for patients with TNBC. Recent findings confirm the important role of factors related to the immune system in the clinical outcome and response to treatment of TNBC patients. Avelumab selectively binds to PDL1, and competitively blocks its interaction with anti-programmed death 1 (anti-PD-1) antibodies. Unlike anti-PD-1 antibodies, which target T-cells, avelumab targets tumor cells, and is therefore expected to have fewer side effects, including a lower risk of Immune-Related Adverse Events (irAEs). Uncertainties remain regarding a potential synergy resulting in increased toxicities by combining radiotherapy and immune-checkpoint inhibitors (ICIs). Effects of concomitant ICIs with thoracic radiotherapy on pulmonary toxicities is not currently known. There are no published data available on the effects of combining anti-PD-L1 with adjuvant radiotherapy (RT) for BC in a clinical setting. We reported a preliminary experience on the first patient treated at the National Cancer Institute of Milan with the association of avelumab and concomitantly RT for TNBC.

Original languageEnglish
Pages (from-to)4
JournalMedical oncology (Northwood, London, England)
Volume36
Issue number1
DOIs
Publication statusPublished - Nov 15 2018

Fingerprint

Triple Negative Breast Neoplasms
Cell Death
Radiotherapy
Ligands
Breast Neoplasms
Adjuvant Radiotherapy
National Cancer Institute (U.S.)
Antibodies
Uncertainty
Immune System
Thorax
T-Lymphocytes
Lung
avelumab
Therapeutics
Neoplasms

Cite this

@article{653a71ccf8864c7f9d1a963afb64fd9d,
title = "Radiotherapy with the anti-programmed cell death ligand-1 immune checkpoint blocker avelumab: acute toxicities in triple-negative breast cancer",
abstract = "Triple-negative breast cancer (TNBC) is clinically the most aggressive breast cancer (BC) subtype. There is an urgent need for effective therapies for patients with TNBC. Recent findings confirm the important role of factors related to the immune system in the clinical outcome and response to treatment of TNBC patients. Avelumab selectively binds to PDL1, and competitively blocks its interaction with anti-programmed death 1 (anti-PD-1) antibodies. Unlike anti-PD-1 antibodies, which target T-cells, avelumab targets tumor cells, and is therefore expected to have fewer side effects, including a lower risk of Immune-Related Adverse Events (irAEs). Uncertainties remain regarding a potential synergy resulting in increased toxicities by combining radiotherapy and immune-checkpoint inhibitors (ICIs). Effects of concomitant ICIs with thoracic radiotherapy on pulmonary toxicities is not currently known. There are no published data available on the effects of combining anti-PD-L1 with adjuvant radiotherapy (RT) for BC in a clinical setting. We reported a preliminary experience on the first patient treated at the National Cancer Institute of Milan with the association of avelumab and concomitantly RT for TNBC.",
author = "{La Rocca}, Eliana and Michela Dispinzieri and Laura Lozza and Gabriella Mariani and {Di Cosimo}, Serena and Massimiliano Gennaro and Riccardo Valdagni and {De Santis}, {Maria Carmen}",
year = "2018",
month = "11",
day = "15",
doi = "10.1007/s12032-018-1228-y",
language = "English",
volume = "36",
pages = "4",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press Inc.",
number = "1",

}

TY - JOUR

T1 - Radiotherapy with the anti-programmed cell death ligand-1 immune checkpoint blocker avelumab

T2 - acute toxicities in triple-negative breast cancer

AU - La Rocca, Eliana

AU - Dispinzieri, Michela

AU - Lozza, Laura

AU - Mariani, Gabriella

AU - Di Cosimo, Serena

AU - Gennaro, Massimiliano

AU - Valdagni, Riccardo

AU - De Santis, Maria Carmen

PY - 2018/11/15

Y1 - 2018/11/15

N2 - Triple-negative breast cancer (TNBC) is clinically the most aggressive breast cancer (BC) subtype. There is an urgent need for effective therapies for patients with TNBC. Recent findings confirm the important role of factors related to the immune system in the clinical outcome and response to treatment of TNBC patients. Avelumab selectively binds to PDL1, and competitively blocks its interaction with anti-programmed death 1 (anti-PD-1) antibodies. Unlike anti-PD-1 antibodies, which target T-cells, avelumab targets tumor cells, and is therefore expected to have fewer side effects, including a lower risk of Immune-Related Adverse Events (irAEs). Uncertainties remain regarding a potential synergy resulting in increased toxicities by combining radiotherapy and immune-checkpoint inhibitors (ICIs). Effects of concomitant ICIs with thoracic radiotherapy on pulmonary toxicities is not currently known. There are no published data available on the effects of combining anti-PD-L1 with adjuvant radiotherapy (RT) for BC in a clinical setting. We reported a preliminary experience on the first patient treated at the National Cancer Institute of Milan with the association of avelumab and concomitantly RT for TNBC.

AB - Triple-negative breast cancer (TNBC) is clinically the most aggressive breast cancer (BC) subtype. There is an urgent need for effective therapies for patients with TNBC. Recent findings confirm the important role of factors related to the immune system in the clinical outcome and response to treatment of TNBC patients. Avelumab selectively binds to PDL1, and competitively blocks its interaction with anti-programmed death 1 (anti-PD-1) antibodies. Unlike anti-PD-1 antibodies, which target T-cells, avelumab targets tumor cells, and is therefore expected to have fewer side effects, including a lower risk of Immune-Related Adverse Events (irAEs). Uncertainties remain regarding a potential synergy resulting in increased toxicities by combining radiotherapy and immune-checkpoint inhibitors (ICIs). Effects of concomitant ICIs with thoracic radiotherapy on pulmonary toxicities is not currently known. There are no published data available on the effects of combining anti-PD-L1 with adjuvant radiotherapy (RT) for BC in a clinical setting. We reported a preliminary experience on the first patient treated at the National Cancer Institute of Milan with the association of avelumab and concomitantly RT for TNBC.

U2 - 10.1007/s12032-018-1228-y

DO - 10.1007/s12032-018-1228-y

M3 - Article

C2 - 30443687

VL - 36

SP - 4

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 1

ER -